Pre-market Hot Trades in US Stocks
Belite Bio is up 7.95% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 1, Belite Bio announced that its experimental drug Tinlarebant achieved its primary endpoint in a late-stage study targeting a rare hereditary eye disease. The drug showed a 36% reduction in the rate of retinal lesion growth compared to placebo in a study involving 104 patients. This news drove the stock price up. Source: Reuters
</li>
<li>
On December 2, Belite Bio released key data from its global Phase III clinical trial, showing significant efficacy of Tinlarebant in treating juvenile Sturge-Weber syndrome. This news further boosted market confidence. Source: Zhitong Finance
</li>
<li>
On December 2, HC Wainwright &amp; Co raised Belite Bio's target price from $98 to $185, reflecting the market's optimistic expectations for the drug's potential. Source: MarketWatch The biotechnology sector has recently performed strongly, with significant capital inflows.
</li>
</ol>
Top Gainers in Pre-market US Stocks
TaoPing is up 58.93% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 1, TaoPing released an important announcement through the EDGAR system of the U.S. Securities and Exchange Commission. The announcement involved the company's future strategic adjustments and market expansion plans, enhancing investor confidence and driving the stock price significantly higher. Source: EDGAR system
</li>
<li>
Recent overall optimism in the tech sector has also supported the rise in TaoPing's stock price. The innovation and growth potential in the tech industry have attracted significant capital inflows, further driving the stock price up. Source: Market Observation
</li>
<li>
Analysts have raised their future earnings expectations for TaoPing, predicting that the company will achieve significant growth in the coming quarters. This positive earnings forecast has strengthened market confidence in TaoPing, promoting the rise in stock price. Source: Analyst Report The tech sector has recently performed strongly, with significant capital inflows.
</li>
</ol>
Fitell is up 56.67% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 1, Fitell announced a $3 million stock repurchase plan. The plan is effective immediately and may be modified, suspended, or terminated at any time. This news drove the stock price up, with a pre-market increase of 22.35%. Source: Company News
</li>
<li>
On December 1, Fitell's stock price rose by 51.8% after the Australian fitness retailer announced a newly approved $3 million stock repurchase plan. This move has enhanced market confidence in the company's future development. Source: Company News
</li>
<li>
On November 28, Fitell submitted an application for the issuance of Class A common stock of up to $6.9 million. Although this news is earlier, combined with the repurchase plan, it shows the company's proactive capital operation strategy. Source: SEC Announcement The fitness industry is active in capital operations, and volatility risks need to be monitored
JSPR pre-market rose by 47.67%. Based on recent key news:
</li>
<li>
On December 2, Jasper Therapeutics announced positive preliminary data from the ETESIAN study, showing that briquilimab reduces airway reactivity and eosinophils in asthma patients, driving the stock price up. The data comes from the company's press release and SEC filings.
</li>
<li>
On December 2, the BEACON study found that patient choice issues rather than drug issues further support the development of briquilimab in asthma treatment, enhancing market confidence.
</li>
<li>
On December 2, Jasper Therapeutics announced it would hold a conference call and webinar to discuss the research results, attracting investor attention and promoting the stock price increase. The biotechnology industry has performed strongly recently, with significant capital inflows
</li>
</ol>

BLTE

Belite Bio pre-market up 7.95%; Taoping pre-market up 58.93%; Fitell pre-market up 56.67%; Jasper Therapeutics pre-market up 47.67%

Pre-market hot trades in US stocks: Rare eye disease drug research succeeds, Belite Bio rises 7.95% in pre-market, target price significantly raised